GlassScriptPhysician profile
Amanda Jude
NPI 1174028443
$4,450.71
in general payments reported to CMS, 2019-2025
39 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 91% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $370 · 2023: $1,486 · 2024: $1,429 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.07 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $570.56 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $552.50 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $329.91 | 2022-2025 | Korlym |
| Abbvie INC. | $273.52 | 2022-2025 | |
| Amgen INC. | $228.35 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $223.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $211.56 | 2022-2025 | |
| Pfizer INC. | $207.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $202.13 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $179.45 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $149.47 | 2024 | Airsupra, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $142.12 | 2023-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $131.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.29 | 2023-2025 | Rexulti, Nuedexta |
| Xeris Pharmaceuticals, INC. | $85.18 | 2022-2024 | Gvoke Hypopen, Recorlev |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $79.87 | 2022-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Mannkind Corporation | $66.03 | 2022-2023 | Afrezza |
| Paratek Pharmaceuticals, INC. | $65.05 | 2025 | Nuzyra |
| Esperion Therapeutics, INC. | $60.77 | 2023-2025 | Nexletol |
| Medtronic, INC. | $53.17 | 2022-2024 | Minimed 780g |
| Astellas Pharma US INC | $51.19 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.14 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.04 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $42.17 | 2023 | |
| Insulet Corporation | $38.29 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $32.80 | 2024 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $32.05 | 2022 | |
| Cranial Technologies, INC | $31.29 | 2023-2025 | Doc Band |
| Seqirus USA INC | $27.91 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Teleflex LLC | $24.18 | 2025 | Urolift |
| Sequel Med Tech, LLC | $23.50 | 2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.60 | 2025 | Xifaxan |
| Viiv Healthcare Company | $21.44 | 2025 | Apretude |
| Gilead Sciences, INC. | $19.35 | 2025 | |
| Beta Bionics, INC. | $17.23 | 2024 | Ilet Bionic Pancreas |
| Amphastar Pharmaceuticals, INC. | $16.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.96 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Cequr Corporation | $5.02 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Jude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.